Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

We report long-term follow up on a clinical trial of pembrolizumab with R-CHOP in 30 adults with untreated DLBCL. With 5-year follow up, we observed durable responses in most patients, without relapses in patients with PD-L1 tumor expression.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 17, 2023 Category: Hematology Authors: Carrie Ho, Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian V. Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Ryan D. Cassaday, Jonathan R. Fromm, Min Fang, Stephen D. Smith Tags: Original Study Source Type: research